The total number of intermediate (CD14+/CD16+) and non-classical (CD14-/CD16+) monocytes was significantly higher in patients with active CLL compared to healthy donors and to patients with non-active disease (p < 0.01 and p < 0.0001, respectively) (Figure S2). Here, CD14 is linked to B-cell chronic lymphocytic leukemia.